NZ272898A - A physical form of (r)-7-acetyl-5-(4-aminophenyl)-8,9-dihydro- 8-methyl-7h-1,3-dioxolo {4,5-h] [2,3] benzodiazepine and pharmaceutical compositions thereof - Google Patents

A physical form of (r)-7-acetyl-5-(4-aminophenyl)-8,9-dihydro- 8-methyl-7h-1,3-dioxolo {4,5-h] [2,3] benzodiazepine and pharmaceutical compositions thereof

Info

Publication number
NZ272898A
NZ272898A NZ272898A NZ27289895A NZ272898A NZ 272898 A NZ272898 A NZ 272898A NZ 272898 A NZ272898 A NZ 272898A NZ 27289895 A NZ27289895 A NZ 27289895A NZ 272898 A NZ272898 A NZ 272898A
Authority
NZ
New Zealand
Prior art keywords
acetyl
methyl
benzodiazepine
dioxolo
dihydro
Prior art date
Application number
NZ272898A
Other languages
English (en)
Inventor
Benjamin Alan Anderson
Marvin Martin Hansen
Jeffrey Thomas Vicenzi
David Lee Varie
Milton Joseph Zmijewski
Edward Grant Groleau
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/412,242 external-priority patent/US6329364B1/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NZ272898A publication Critical patent/NZ272898A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NZ272898A 1994-08-31 1995-08-30 A physical form of (r)-7-acetyl-5-(4-aminophenyl)-8,9-dihydro- 8-methyl-7h-1,3-dioxolo {4,5-h] [2,3] benzodiazepine and pharmaceutical compositions thereof NZ272898A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29864594A 1994-08-31 1994-08-31
US08/412,242 US6329364B1 (en) 1994-08-31 1995-03-28 Crystalline form of dihydro-2,3-benzodiazepine derivative

Publications (1)

Publication Number Publication Date
NZ272898A true NZ272898A (en) 1996-12-20

Family

ID=26970796

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ272898A NZ272898A (en) 1994-08-31 1995-08-30 A physical form of (r)-7-acetyl-5-(4-aminophenyl)-8,9-dihydro- 8-methyl-7h-1,3-dioxolo {4,5-h] [2,3] benzodiazepine and pharmaceutical compositions thereof

Country Status (20)

Country Link
EP (1) EP0699678B1 (fr)
JP (1) JP3449835B2 (fr)
CN (1) CN1073996C (fr)
AT (1) ATE262531T1 (fr)
AU (1) AU695424B2 (fr)
BR (1) BR9503843A (fr)
CA (1) CA2157248C (fr)
CZ (1) CZ288679B6 (fr)
DE (1) DE69532739T2 (fr)
DK (1) DK0699678T3 (fr)
ES (1) ES2214491T3 (fr)
FI (1) FI112489B (fr)
HK (1) HK1013820A1 (fr)
HU (1) HU223843B1 (fr)
IL (1) IL115102A (fr)
NO (1) NO309192B1 (fr)
NZ (1) NZ272898A (fr)
PL (1) PL181086B1 (fr)
PT (1) PT699678E (fr)
TR (1) TR199501070A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6017903A (en) 1996-09-27 2000-01-25 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
US5824662A (en) * 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
PL332413A1 (en) 1996-09-27 1999-09-13 Guilford Pharm Inc Compositions containing inhibitors of naaladase as well as methods of treating glutamatic anomaly and influencing neuronic functions among animals
UA67749C2 (uk) * 1997-08-12 2004-07-15 Егіш Дьйодьсердьяр Рт. Похідна 8-заміщеного-9н-1,3-діоксол/4,5-h//2,3/бензодіазепіну з властивостями амра/каїнатного антагоніста, спосіб одержання похідних, фармацевтична композиція (варіанти), спосіб її одержання та спосіб лікування
NZ503301A (en) * 1997-08-12 2002-09-27 Egyt Gyogyszervegyeszeti Gyar 1,3-dioxolo[4,5-h][2,3]benzodiazepine derivatives useful as AMPA/Kainate receptor inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU219778B (hu) 1990-12-21 2001-07-30 Gyógyszerkutató Intézet Közös Vállalat Eljárás N-acil-2,3-benzodiazepin-származékok, savaddíciós sóik és az ezeket tartalmazó gyógyászati készítmények előállítására, valamint a vegyületek egy csoportja, és az ezeket tartalmazó gyógyászati készítmények
HU219777B (hu) * 1993-07-02 2001-07-30 Gyógyszerkutató Intézet Kft. Optikailag aktív 1-(4-nitro-fenil)-4-metil-7,8-metiléndioxi-3,4-dihidro-5H-2,3-benzodiazepin és eljárás előállítására

Also Published As

Publication number Publication date
BR9503843A (pt) 1996-09-10
FI112489B (fi) 2003-12-15
CZ222195A3 (en) 1996-03-13
JPH0881469A (ja) 1996-03-26
FI954066A (fi) 1996-03-01
JP3449835B2 (ja) 2003-09-22
PL181086B1 (pl) 2001-05-31
CA2157248C (fr) 2000-02-22
PT699678E (pt) 2004-07-30
EP0699678A1 (fr) 1996-03-06
NO953394L (no) 1996-03-01
AU3035795A (en) 1996-03-14
NO309192B1 (no) 2000-12-27
CZ288679B6 (cs) 2001-08-15
DE69532739T2 (de) 2005-03-17
AU695424B2 (en) 1998-08-13
ATE262531T1 (de) 2004-04-15
IL115102A0 (en) 1995-12-08
CN1128264A (zh) 1996-08-07
HUT72675A (en) 1996-05-28
DK0699678T3 (da) 2004-06-28
CN1073996C (zh) 2001-10-31
NO953394D0 (no) 1995-08-30
EP0699678B1 (fr) 2004-03-24
DE69532739D1 (de) 2004-04-29
PL310228A1 (en) 1996-03-04
HK1013820A1 (en) 1999-09-10
TR199501070A2 (tr) 1996-06-21
ES2214491T3 (es) 2004-09-16
FI954066A0 (fi) 1995-08-30
HU223843B1 (hu) 2005-02-28
HU9502549D0 (en) 1995-10-30
IL115102A (en) 1998-12-27
CA2157248A1 (fr) 1996-03-01

Similar Documents

Publication Publication Date Title
US6329364B1 (en) Crystalline form of dihydro-2,3-benzodiazepine derivative
AU695424B2 (en) Crystalline form of a dihydro-2,3-benzodiazepine derivative
CA2198751C (fr) Derives de dihydro-2,3-benzodiazepine
EP0699676B1 (fr) Forme physique d'un dérivé de dihydro-2,3-benzodaizépine
RU2146677C1 (ru) Физическая форма (r)-7-ацетил-5-(4-аминофенил)-8,9-дигидро-8-метил-7н-1,3- диоксоло[4,5-h]-[2,3]-бензодиазепина, способ ее получения и фармацевтическая композиция
AU689639C (en) Dihydro-2,3-benzodiazepine derivatives

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired